For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

The severity of a patient’s chronic spontaneous urticaria impacted several outcomes, including quality of life and treatment ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

Chronic urticaria (CU) is a dermatological condition characterized by recurrent wheals (hives), angioedema (deep tissue swelling), or both, persisting for over 6 weeks. 1 Unlike acute urticaria ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...